biospace.com
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to Stelara enter the U.S. market, potentially influencing access and payer coverage.
Adult patients with Crohn’s disease or inflammatory bowel disease, patients currently on or considering biologics, gastroenterologists and prescribing clinicians, and researchers watching IL-23 therapies and biosimilar market shifts.
What To Know
FDA expanded the label for Johnson & Johnson’s Tremfya (an IL-23 blocker) to include adults with moderately to severely active Crohn’s disease, based on Phase III trial data described in the company release and reported here.
The article also notes Tremfya’s IV and subcutaneous dosing options, J&J positioning Tremfya as a potential successor to Stelara amid multiple Stelara biosimilars entering the U.S. market, and mentions ongoing J&J development of other IL-23-targeted therapies.
The FDA approval means Tremfya is now an approved treatment option for adults with moderately to severely active Crohn’s disease. The reporting highlights that Tremfya is an IL-23 inhibitor available both intravenously and subcutaneously for this indication, and that its approval was supported by Phase III program results including endoscopic endpoints.
The piece also focuses on market dynamics: several biosimilars to Stelara (ustekinumab) recently launched in the U.S., which could affect prescribing and payer decisions.
If you’re reading this as a patient, the key practical points are that a new FDA-approved biologic option exists for Crohn’s disease and that insurance coverage, cost, and availability may be influenced by competing biosimilars and payer policies.
Discuss with your gastroenterology team whether Tremfya is appropriate for your situation, and ask about dosing options, self-administration, and coverage. The article is a news report summarizing a company release and broader market context rather than presenting full trial data or clinical guidance.
The article is a news summary based largely on a J&J press release and mentions Phase III trials without detailing full data. It also emphasizes commercial implications (biosimilars and payer actions). This is not clinical guidance; treatment decisions should follow discussion with clinicians.
The company and market context may shape access and cost rather than directly indicating comparative effectiveness.
